SCHEMBL3544087

SCHEMBL3544087

CS(=O)(=O)OCc1cccc(SC(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.45
CETP P11597 2/20 0.38
PTPRZ1 P23471 3/20 0.36
RXFP1 Q9HBX9 2/20 0.36
PTPN1 P18031 2/20 0.34
IDO1 P14902 2/20 0.33
MRGPRX4 Q96LA9 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
UBE2M P61081 1/20 0.33
DCUN1D1 Q96GG9 1/20 0.33
KMT2A Q03164 1/20 0.33
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32
PTGS2 P35354 1/20 0.32
MAOB P27338 1/20 0.32
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16935702 0.83 CA2 (0.38) PTPN1IDO1CA1CA2CA9
SCHEMBL18003150 0.81 PTPRZ1 (0.56) PTPRZ1PTPN1CA1CA2CA9
SCHEMBL512504 0.80 CETP (0.38) FFAR4CETPPTPRZ1RXFP1PTPN1
SCHEMBL514222 0.80 CETP (0.44) FFAR4CETPPTPRZ1RXFP1PTPN1
SCHEMBL8063113 0.79 CA2 (0.45) PTPN1IDO1CA1CA2CA9
SCHEMBL8685464 0.77 IDO1 (0.58) IDO1MAOBLMNAMAPTHTT
SCHEMBL27482769 0.77 ALDH1A1 (0.51) FFAR4CETPRXFP1UBE2MDCUN1D1
SCHEMBL27466969 0.76 FFAR4 (0.39) FFAR4CETPPTPRZ1PTPN1CA1
SCHEMBL514221 0.76 FFAR4 (0.44) FFAR4CETPPTPRZ1RXFP1PTPN1
SCHEMBL514241 0.76 FFAR4 (0.46) FFAR4CETPPTPRZ1RXFP1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE FFAR4 3140/4885CETP 4722/4885PTPRZ1 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.